News
-
-
-
COMMUNIQUÉ DE PRESSE
Seraxis Wins Maryland Stem Cell Research Fund Grant to Accelerate Development of Allogenetically Compatible Pancreatic Islet Replacement Therapy for Functional Cure of T1D
Seraxis, Inc. awarded $400,000 MSCRF grant to advance SR-03 cell line for diabetes treatment. Meeting at ADA Annual Meeting in Orlando -
COMMUNIQUÉ DE PRESSE
Seraxis' Manufacturing Suite Completes GMP Quality System Audit Ahead of SR-02 IND Filing and Transplantation of Pancreatic Clusters to Patients With Type 1 Diabetes
Seraxis, Inc., a regenerative medicine company, has announced the completion of a GMP-compliant manufacturing audit for its pancreatic islet replacement therapy program. The audit revealed no critical or major observations, positioning the company's SR-02 as one of the industry's leading clinical-stage stem cell-derived pancreatic islet transplant programs. CEO Dr. William Rust will present further data on the development of SR-02 and follow-on immune-cloaked SR-03 at Biotech Showcase in San Francisco.
